BCR-ABL PCR testing in chronic myelogenous leukemia: Molecular diagnosis for targeted cancer therapy and monitoring

Martin H. Luu, Richard Press

Research output: Contribution to journalArticle

14 Scopus citations


The use of tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML) represents the paradigm for modern targeted cancer therapy. Importantly, molecular monitoring using BCR-ABL real-time quantitative reverse transcription polymerase chain reaction (RQ-PCR) for assessing treatment efficacy and quantitating minimal residual disease is a major determinate of practical therapeutic decision-making in the long-term management of this now chronic disease. Herein, we present an overview of CML and the use of TKIs for targeted CML therapy, with an emphasis on the role, application and future aspects of PCR-based molecular monitoring.

Original languageEnglish (US)
Pages (from-to)749-762
Number of pages14
JournalExpert Review of Molecular Diagnostics
Issue number7
Publication statusPublished - 2013



  • RQ-PCR

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pathology and Forensic Medicine

Cite this